Escitalopram titration and clinical monitoring standards
Managing escitalopram therapy requires precise titration to balance rapid anxiety relief against long-term sexual health impacts.
In the clinical management of Major Depressive Disorder (MDD) and Generalised Anxiety Disorder (GAD), escitalopram has become a cornerstone of primary care due to its high selectivity for the serotonin transporter. However, despite its reputation for being “cleaner” than older Selective Serotonin Reuptake Inhibitors (SSRIs), clinical failures often arise from a lack of patient preparation regarding initial side effects and the gradual nature of neuroplastic change. When expectations are not aligned with the biological reality of the drug, patients frequently discontinue treatment within the first 14 days, often right before the therapeutic window begins to open.
The complexity of escitalopram therapy is rooted in the heterogeneity of patient response, particularly regarding the onset of action and the persistence of sexual dysfunction. While it is pharmacologically more potent than its predecessor citalopram, its interaction with the allosteric site of the serotonin transporter means that even minor dosage adjustments can have significant impacts on a patient’s daily quality of life. Misunderstanding the dose-response curve or misidentifying “activation syndrome” as a worsening of the primary disorder can lead to inappropriate dosage escalations that exacerbate somatic distress.
This article clarifies the clinical standards for escitalopram usage, offering a structured approach to titration, laboratory monitoring, and the diagnostic differentiation between this agent and other common SSRIs like sertraline. By establishing a workable patient workflow, we aim to reduce the incidence of avoidable complications and provide a roadmap for long-term metabolic and sexual health during the recovery process.
Clinical Checkpoints for Escitalopram Success:
- Confirm Baseline EKG in patients with existing cardiac concerns to monitor for dose-dependent QTc prolongation, especially if exceeding 20mg.
- Establish a Micro-Start Protocol (5mg) for patients with high somatic anxiety to prevent the “jitteriness” associated with acute serotonin surges.
- Monitor Sodium Levels periodically in patients over 65, as SSRIs are a common clinical cause of SIADH and subsequent hyponatremia.
- Implement Sexual Health Baseline Surveys (such as the ASEX scale) before the first dose to distinguish medication effects from depression-induced low libido.
See more in this category: Medications
In this article:
- Context snapshot (definition, who it affects, diagnostic evidence)
- Quick guide
- Understanding in clinical practice
- Practical application and steps
- Technical details
- Statistics and clinical scenario reads
- Practical examples
- Common mistakes
- FAQ
- References and next steps
- Normative/Regulatory basis
- Final considerations
Last updated: February 14, 2026.
Quick definition: Escitalopram is a highly Selective Serotonin Reuptake Inhibitor (SSRI) that increases synaptic serotonin concentrations by blocking the reuptake pump, facilitating neural remodeling in mood-regulating circuits.
Who it applies to: Primarily indicated for adults and adolescents (12+) with Major Depressive Disorder and adults with Generalised Anxiety Disorder, Panic Disorder, or Social Anxiety.
Time, cost, and diagnostic requirements:
- Diagnostic Baseline: Mandatory screening for Bipolar Disorder history to prevent medication-induced manic switching.
- Stabilization Window: Physiological side effects typically peak within 7 to 10 days; emotional stabilization begins around week 4.
- Laboratory Monitoring: Serum sodium levels and EKG are required only for specific high-risk demographics (elderly or cardiac-impaired).
- Financial Profile: Highly accessible as a generic medication with high “efficacy-to-cost” ratio in public and private health systems.
Key factors that usually decide clinical outcomes:
- Early Tolerance: Managing the initial activation phase determines whether a patient will remain adherent long enough to see mood benefits.
- CYP2C19 Metabolism: Genetic variability in this enzyme determines whether a patient is a “Poor Metabolizer” (risking toxicity) or a “Rapid Metabolizer” (risking treatment failure).
- Sexual Side Effect Mitigation: Proactive management of libido and arousal changes prevents the secondary depression associated with relational strain.
- Tapering Precision: The speed of the final discontinuation phase determines the severity of SSRI Discontinuation Syndrome and the risk of immediate relapse.
Quick guide to Escitalopram Optimization
- Starting Dose: Standard initiation is 10mg once daily; however, 5mg is often preferred for geriatric patients or those with sensitive autonomic nervous systems.
- Therapeutic Ceiling: Most clinical benefits are achieved at 20mg; doses above this are rarely more effective for depression and significantly increase the risk of QTc prolongation.
- The Comparison Point: Unlike sertraline, escitalopram has minimal dopaminergic activity, making it less “activating” for some but potentially more likely to cause “emotional blunting.”
- Withdrawal Prevention: Abrupt cessation is strongly discouraged; a gradual taper over 4-8 weeks is the clinical standard to avoid brain zaps and severe vertigo.
- Safety Signal: Any emergence of shivering, diarrhea, or muscle rigidity should be evaluated immediately for Serotonin Syndrome, especially if combined with other supplements.
Understanding Escitalopram in clinical practice
Escitalopram represents the S-enantiomer of citalopram. In simple clinical terms, it is the “active half” of the older drug, refined to interact more cleanly with the serotonin transporter (SERT). Because it avoids the R-enantiomer, it has fewer off-target effects on histamine or muscarinic receptors, which historically translates to less sedation and dry mouth compared to first-generation SSRIs. In practice, this high specificity allows for lower milligram dosing while achieving comparable or superior serotonin saturation in the synaptic cleft.
The “standard of care” focuses on the first 21 days. During this period, the brain’s 5-HT1A autoreceptors are being desensitized. This biological “lag” is why patients often feel worse before they feel better. A clinician’s role is to provide the “bridge” through this adaptation period, sometimes utilizing low-dose benzodiazepines or hydroxyzine for the first 10 days to handle the temporary increase in somatic anxiety that escitalopram can induce as the neural circuits reset.
Decision-Grade Clinical Workflow:
- Target Metric: Aim for a 50% reduction in PHQ-9 or GAD-7 scores by the 8-week mark; if less, reassess dose or adherence.
- Sexual Health Pivot: If sexual dysfunction occurs, consider a “drug holiday” (with caution) or the addition of adjunctive agents like bupropion to counter serotonin-induced numbness.
- Cardiac Safety Rule: For any patient on 20mg or higher, an EKG is mandatory if they report palpitations, syncope, or a family history of rhythm disorders.
- Switching Logic: When moving from sertraline to escitalopram, a direct switch is often possible if doses are equivalent (e.g., 50mg sertraline to 10mg escitalopram).
Regulatory and practical angles that change the outcome
Guideline variability in 2026 highlights the importance of Pharmacogenomics. Many modern protocols now suggest that if a patient fails two SSRIs, a CYP2C19 genetic test is warranted. This is because “ultra-rapid metabolizers” may clear 10mg of escitalopram so quickly that they never reach therapeutic steady-state, while “poor metabolizers” may experience 20mg-level side effects on a 5mg dose. Documentation of these metabolic patterns is becoming a requirement for justifying “high-dose” prescriptions in refractory cases.
Regulatory bodies like the FDA and EMA continue to monitor the long-term metabolic impact of escitalopram. While it is generally “weight-neutral” in short-term trials, real-world data shows that a subset of patients experiences significant weight gain after month 6. Clinical documentation must include baseline weight and waist circumference to track these shifts, allowing for early intervention via dietary counseling or a medication switch before the patient develops secondary metabolic syndrome.
Workable paths patients and doctors actually use
In the real world, the “one-pill-a-day” simplicity often breaks down due to lifestyle factors. Successful clinicians and patients often employ one of these verified paths:
- The Morning Dosing Path: For patients who experience medication-induced insomnia, taking the dose before 9:00 AM prevents the peak serotonin levels from interfering with the natural melatonin cycle at night.
- The Evening Dosing Path: For the approximately 15% of patients who experience daytime lethargy or “brain fog” on escitalopram, taking the dose at 8:00 PM allows the peak concentration to pass during sleep.
- The Liquid Titration Path: For ultra-sensitive patients or those with Panic Disorder, using the liquid formulation allows for 1mg or 2mg increments, bypassing the gastrointestinal “shock” of a 10mg tablet.
- The Sexual Health Protection Path: Proactively starting low-intensity resistance training and cardiovascular exercise, which has been shown to mitigate some of the SSRI-induced erectile and arousal changes.
Practical application of Escitalopram in real cases
Applying escitalopram therapy is a phased process that moves from “crisis management” to “functional recovery.” The workflow often fails when the physician stops at “symptom reduction” and does not reach “functional remission.” For a patient to be truly successful, they need to return to their baseline level of social and occupational engagement. This requires a sequenced approach where the dose is optimized until the patient no longer “feels like they are on a drug” but simply “feels like themselves.”
Diagnostic accuracy during the application phase is critical. If a patient reports “agitation” in week 2, the clinician must decide if this is Activation Syndrome (a side effect) or Hypomania (a diagnostic change). Treating a side effect with a dose increase or a bipolar switch with more serotonin can have disastrous clinical outcomes. Documentation of these nuances is what separates expert psychiatric care from standard “prescription-filling.”
- Define the clinical starting point: Complete a full Bipolar screen and obtain baseline PHQ-9/GAD-7 scores. Identify the patient’s primary concern (e.g., “I can’t sleep” vs “I can’t work”).
- Build the medical record: Note all current supplements (especially St. John’s Wort or 5-HTP) and medications. Document the patient’s weight and baseline sexual function scores.
- Apply the standard of care: Start at 10mg (or 5mg if sensitive). Provide a written “Expectation Guide” explaining that they will likely feel more anxious/nauseous for the first 7 days.
- Compare initial diagnosis vs. progression: At week 4, re-administer the PHQ-9. If the score has not dropped by 25%, evaluate medication adherence—did the patient stop because of a side effect they didn’t mention?
- Document treatment adjustment: If side effects are absent but mood is only “partially” improved, escalate to 15mg or 20mg. Record the clinical rationale for the increase, focusing on functional deficits.
- Escalate only when clinically ready: If the patient remains refractory at 20mg after 8 weeks, consider augmentation with a non-SSRI (like buspirone or aripiprazole) rather than pushing escitalopram into “toxic” QTc ranges.
Technical details and relevant updates
From a pharmacological standpoint, escitalopram has a half-life of approximately 27-32 hours. This is significant because it allows for stable blood levels with once-daily dosing, but it also means that “steady-state” is not reached for 5 to 7 days. Its bioavailability is roughly 80% and is not significantly affected by food, giving the patient flexibility in how they take it. However, because it is primarily metabolized by CYP2C19, inhibitors of this enzyme (like omeprazole) can increase escitalopram levels by up to 50%.
Recent 2025 surveillance data has highlighted a specific reporting pattern regarding “Post-SSRI Sexual Dysfunction” (PSSD). While rare, the recognition of persistent sexual side effects after stopping the medication has led to a requirement for clinicians to discuss the “exit strategy” before the first dose is ever taken. Physicians must now monitor libido, lubrication, and climax latency at every quarterly follow-up to ensure that the medication’s burden does not outweigh its psychological benefits.
- QTc Interval Thresholds: Treatment should be reassessed if the QTc interval exceeds 450ms in men or 470ms in women; absolute discontinuation is required if it exceeds 500ms.
- SIADH Monitoring: In patients over 65, check serum sodium at baseline, week 2, and month 3 to catch “silent” hyponatremia.
- Platelet Interaction: SSRIs inhibit serotonin uptake in platelets; patients on NSAIDs or anticoagulants must be monitored for increased bruising or GI bleeding risk.
- Drug-Drug Interaction Pivot: Escitalopram is a weak inhibitor of CYP2D6, making it safer to use with drugs like metoprolol or tamoxifen compared to fluoxetine or paroxetine.
- Emergency Escalation: Immediate ER referral is needed if the patient presents with delirium, hyperthermia, or “clonus” (involuntary muscle contractions) while on therapy.
Statistics and clinical scenario reads
These scenarios represent 2026 clinical observations in outpatient psychiatric settings. They are intended to provide “pattern recognition” for clinicians and monitoring signals for patients, rather than serving as final medical conclusions. Understanding these distributions helps set realistic expectations for the speed and quality of recovery.
Treatment Response and Side Effect Distribution (6-Month Follow-up)
Successful long-term management typically involves stable 10mg-20mg dosing with manageable side effects.
Libido or orgasm changes are the leading “non-psychiatric” reasons for treatment fatigue.
Usually driven by unmanaged nausea or a temporary spike in physical anxiety upon initiation.
Often tied to CYP2C19 ultra-rapid metabolism or underlying un-diagnosed bipolarity.
Clinical Indicators and Outcome Shifts (Pre-treatment vs. 12 Weeks)
- PHQ-9 Depression Score: 18.2 (Moderate/Severe) → 7.4 (Mild/Remission). Primary driver of functional recovery.
- Daily Social Engagement: 1.2 hours → 3.8 hours. Reflects the reduction in “anxious avoidance.”
- Sleep Latency (Time to fall asleep): 55 minutes → 24 minutes. Usually improves once the “serotonin jitter” phase passes.
- Serum Sodium Levels (Elderly subgroup): 141 mEq/L → 136 mEq/L. Highlights the need for hyponatremia vigilance.
- Orgasm Latency (Time to climax): 120% Increase. The most common “biological tax” for emotional stability.
Monitorable Points for Success
- PHQ-9 Reduction: Target > 5 points reduction within the first 30 days.
- Resting Heart Rate: Monitor for 5-10 BPM fluctuations during the initiation week.
- Body Mass Index (BMI): Track monthly for the first 6 months to catch the “metabolic drift.”
- Medication Adherence Rate: > 90% of days is required for neural remodeling.
Practical examples of Escitalopram in real cases
Success Scenario: The Optimized GAD Recovery
A 32-year-old with severe Generalized Anxiety Disorder (GAD). Initiation started at 5mg for 7 days, then 10mg. The patient experienced mild nausea on days 2-4 but used the provided hydroxyzine “bridge.” By week 4, the GAD-7 score dropped from 16 to 8. At week 8, the dose was stabilized at 10mg. Why it worked: The slow start prevented dropout, and the EKG at week 12 confirmed cardiac safety, allowing the patient to return to full-time work without fear of panic attacks.
Complication Scenario: The Sexual Dysfunction Pivot
A 40-year-old on 20mg for depression. The mood improved significantly (PHQ-9 of 4), but the patient experienced complete anorgasmia. This led to marital strain and a desire to quit the medication entirely. The Clinical Course: Instead of quitting, the physician reduced the dose to 10mg and added 150mg of bupropion. The Result: The patient maintained mood stability while sexual function returned to 80% of baseline, preventing a relapse that would have likely followed “cold-turkey” cessation.
Common mistakes in Escitalopram therapy
Aggressive Initiation: Starting at 20mg immediately often triggers a severe anxiety spike (Activation Syndrome) that causes the patient to permanently fear the medication.
Ignoring the “Emotional Numbing”: Dismissing a patient’s report of “feeling like a zombie” as just “not being depressed anymore” instead of adjusting the dose-response ratio.
Abrupt Tapering: Stopping the drug in less than 7 days, which triggers “Brain Zaps” and vertigo so severe the patient often ends up in the Emergency Room.
Unmonitored Omeprazole Use: Failing to recognize that common acid reflux meds can double the blood level of escitalopram, turning a safe 20mg dose into a 40mg risk.
Underestimating Sertraline Differences: Assuming that because sertraline worked, escitalopram will behave the same, and ignoring the lack of dopaminergic “lift” in the latter.
FAQ about Escitalopram Therapy
How do I tell the difference between side effects and my actual anxiety?
Medication-induced anxiety, often called Activation Syndrome, typically starts within 48 hours of your first dose or a dose increase. It feels more “physical” than your usual anxiety—characterized by a racing heart, sweaty palms, and a “jittery” feeling in your chest, even if you don’t have something specific to worry about. It usually peaks in the morning and subsides by the evening.
Your “real” anxiety is more likely to be tied to your thought patterns and has been present long before the medication. The key clinical anchor is timing: if the jitters started exactly when the pill did, it’s a side effect. If the feeling persists beyond day 14 without any improvement, your physician will need to evaluate if the drug is the right fit for your autonomic nervous system.
Will escitalopram make me gain weight permanently?
Escitalopram is considered “weight-neutral” in the first 3 months of use for most patients. However, after 6 to 12 months, some people experience an increase in appetite, particularly for carbohydrates. This is often because serotonin also affects the brain’s “reward” pathways, making food more appealing as the depression-induced lack of pleasure resolves.
From a monitoring perspective, if you see a weight increase of more than 5% of your body weight in 6 months, it is a clinical signal to adjust your metabolic plan. It is not “permanent” fat; it is a metabolic shift that can be countered with dietary adjustments or, in some cases, switching to a more weight-neutral antidepressant like bupropion if the psychiatric benefits can be maintained.
Why does my doctor compare escitalopram to sertraline?
Sertraline and escitalopram are the two most commonly prescribed SSRIs. Sertraline has a slight “dopamine” effect, which can make it more energizing for people who are very lethargic but can also cause more diarrhea and “shaky hands.” Escitalopram is more “selective,” meaning it purely targets serotonin, often resulting in fewer digestive issues but more “emotional blunting” for some users.
The choice between them often depends on your specific symptom cluster. If you struggle with severe physical anxiety, the “cleaner” serotonin profile of escitalopram is often preferred. If your depression is characterized by “brain fog” and a lack of motivation, your physician might suggest sertraline as the more appropriate clinical tool for your neurochemistry.
What exactly are the “brain zaps” during withdrawal?
Brain zaps are brief, electric-shock-like sensations that occur when you move your eyes or head during a rapid reduction in SSRI dosage. They are a core symptom of Discontinuation Syndrome. They occur because your brain’s receptors have “down-regulated” (become used to high serotonin levels), and the sudden drop in the drug leaves your neural firing patterns temporarily unstable.
While they are distressing, they are not physically dangerous. The clinical standard to stop them is to immediately resume a small dose of the medication and then slow the taper. For example, if you were on 10mg, you might drop to 7.5mg for two weeks, then 5mg for two weeks, rather than jumping straight to zero. This “soft landing” allows the brain’s receptors to re-adjust without the “electrical” shock sensations.
Is it safe to drink alcohol while taking escitalopram?
The official medical advice is to avoid alcohol, as both substances are processed by the liver and both affect the central nervous system. Alcohol is a depressant that effectively “undoes” the work of the antidepressant, potentially leading to a severe “hangover depression” that can last for several days. Furthermore, escitalopram can make you feel the effects of alcohol much more quickly, leading to impaired judgment.
From a dosage/metric concept, having one occasional drink is unlikely to be toxic, but chronic drinking can destabilize your serotonin levels and lead to treatment failure. For the best clinical outcome, it is recommended to abstain entirely during the first 8 weeks of titration while your brain is at its most sensitive stage of remodeling.
Can escitalopram affect my heart rhythm?
Yes, in a dose-dependent manner. Escitalopram can cause QTc prolongation, which is a slowing of the heart’s electrical recharging phase. While this is not an issue for most healthy people, it can be dangerous if the “recharge time” becomes too long, potentially leading to a serious arrhythmia. This risk is highest at doses of 20mg or when taken with other medications that also affect the heart.
The monitorable point is an EKG. If you are starting escitalopram and have a history of fainting, palpitations, or are taking medications for heart failure, your doctor will require an EKG before starting and periodically after. If the QTc interval reaches the 500ms threshold, the medication must be discontinued immediately to ensure cardiac safety.
Will the sexual side effects ever go away?
For about 30% of patients, sexual side effects like decreased libido or delayed climax improve after the first 2 or 3 months as the body adapts. However, for many, these side effects persist as long as the medication is taken. It is a biological reality that increased serotonin in certain parts of the brain inhibits dopamine and nitric oxide, which are required for sexual arousal and climax.
The “workable path” involves dose optimization. Often, a reduction from 20mg to 10mg can restore sexual function without a return of the depression. If that fails, adding “booster” medications or scheduling “drug holidays” (only under strict supervision) can help. The key is to discuss this openly with your doctor, as persistent sexual dysfunction is a major clinical driver of treatment non-adherence.
What should I do if I miss a dose?
If you remember within 12 hours of your usual time, take the missed dose with food. If it has been more than 12 hours, skip the missed dose and wait for your next scheduled time. You should never take a double dose to make up for a missed one, as this can cause an acute serotonin spike leading to nausea, headaches, or blurred vision.
Because escitalopram has a half-life concept of 30 hours, missing one single dose will not immediately trigger withdrawal symptoms for most people. However, missing three or more doses in a row will cause your blood levels to drop significantly, which may result in a “rebound” of your anxiety or the beginning of dizziness and brain zaps.
Is escitalopram safe for children and teenagers?
Escitalopram is one of the few SSRIs with FDA approval for adolescents (12-17) for Major Depressive Disorder. However, it carries a “Black Box Warning” for all people under age 24. This is because, in the first 4 weeks of therapy, there is a statistically small but significant risk of increased suicidal thoughts, as the medication can increase “energy” before it improves “mood.”
The clinical requirement for teens is weekly monitoring during the first month. Parents should look for signs of agitation, unusual hostility, or a sudden “burst of energy” that doesn’t feel like the child’s normal self. When used with this level of surveillance, escitalopram is an effective and standard clinical tool for pediatric mental health.
Does escitalopram interact with my other medications?
Escitalopram has fewer drug interactions than fluoxetine or paroxetine, but it is not “interaction-free.” The most dangerous interaction is with MAOIs (older antidepressants), which can lead to fatal Serotonin Syndrome. It also interacts with blood thinners like warfarin and aspirin, as serotonin helps platelets stick together; without it, you bruise and bleed more easily.
A specific “hidden” interaction is with omeprazole (Prilosec). Because omeprazole inhibits the enzyme that clears escitalopram, taking both can effectively double the amount of escitalopram in your blood. Always ensure your physician has a complete list of your over-the-counter medications to avoid these common but preventable pharmacokinetic complications.
References and next steps
- Baseline Package: Request an EKG and a Bipolar screening questionnaire before the first dose.
- Metric Tracking: Download a GAD-7 or PHQ-9 tracker and complete it every Sunday for the first two months.
- Safety Check: If you are over age 65, schedule a serum sodium test for week 2 of therapy.
- Specialist Referral: If sexual side effects persist after month 3, request a consult for bupropion augmentation or a dose optimization review.
Related Reading:
- Understanding SSRI Discontinuation Syndrome: A Slow Taper Guide
- The Science of Serotonin: How Neuroplasticity Drives Mood Recovery
- Sertraline vs. Escitalopram: Choosing the Right SSRI for Your Anxiety
- Post-SSRI Sexual Dysfunction (PSSD): Emerging Research and Patient Care
- Managing Activation Syndrome: Why You Feel Worse Before You Feel Better
- The Role of CYP2C19 Genetic Testing in Refractory Depression
Normative and regulatory basis
The clinical application of escitalopram is strictly regulated by the Food and Drug Administration (FDA) in the United States and the European Medicines Agency (EMA) in the EU. These governing bodies mandate the “Black Box” warnings regarding suicidal ideation in young adults and the dosage caps for QTc safety. Adherence to these guidelines is not just a clinical suggestion but a requirement for the standard of care in primary and psychiatric settings. Misdiagnosis or a failure to monitor cardiac and metabolic baselines can result in regulatory non-compliance and compromised patient outcomes.
Furthermore, clinical proof for escitalopram’s efficacy in MDD and GAD is grounded in the American Psychiatric Association (APA) Practice Guidelines. These standards emphasize the importance of evidence-based titration and the necessity of documenting treatment-resistant cases via verified symptom scales. For the most up-to-date prescribing info and safety alerts, clinicians and patients should consult the official FDA portal at FDA.gov or the WHO Essential Medicines List at WHO.int (target=”_blank”).
Final considerations
Escitalopram remains one of the most effective and tolerable pharmacological tools in the modern psychiatric arsenal. Its high selectivity for serotonin allows for deep neural remodeling with a relatively low side-effect burden compared to older classes of antidepressants. However, its success is not guaranteed by the pill itself, but by the precision of the patient-physician partnership. Understanding the biological timelines—specifically the 14-day activation phase and the 8-week mood threshold—is essential for maintaining treatment adherence.
As we move further into a data-driven medical landscape, the integration of pharmacogenetic testing and cardiac monitoring will continue to refine how we use this agent. By proactively addressing sexual health concerns and metabolic shifts, the clinical team can ensure that the “tax” for emotional stability does not become too high for the patient to bear. The goal of escitalopram therapy is not merely the absence of depression, but the restoration of a vibrant, functional, and self-directed life.
Clinical Precision: Always use the “lowest effective dose” to reach functional remission while minimizing long-term metabolic and sexual burden.
Adherence Vigilance: The first 14 days are the most critical; provide patients with “bridge” medications or frequent check-ins to prevent early dropout.
Holistic Monitoring: Weight, libido, and heart rhythm are not “secondary” issues—they are primary drivers of whether a patient will stay on treatment long enough to heal.
- Take your dose at a consistent time every day to maintain stable synaptic serotonin levels.
- Avoid high-dose ibuprofen (NSAIDs) while on escitalopram if you have a history of gastric sensitivity or ulcers.
- Communicate any sudden changes in vision or heart rhythm to your provider immediately for a safety review.
This content is for informational and educational purposes only and does not substitute for individualized medical evaluation, diagnosis, or consultation by a licensed physician or qualified health professional.
